Compare ACXP & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACXP | PPCB |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | Australia |
| Employees | 4 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.2M |
| IPO Year | 2021 | N/A |
| Metric | ACXP | PPCB |
|---|---|---|
| Price | $1.52 | $0.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $143.67 | N/A |
| AVG Volume (30 Days) | 48.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.16 |
| 52 Week High | $8.34 | $10.69 |
| Indicator | ACXP | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 23.69 | 33.67 |
| Support Level | $0.31 | $0.18 |
| Resistance Level | $2.89 | $0.40 |
| Average True Range (ATR) | 0.17 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 11.39 | 22.28 |
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.